<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HISTAMINE POSITIVE SKIN TEST CONTROL- histamine phosphate injection, solution </strong><br><strong>HISTAMINE POSITIVE SKIN TEST CONTROL- histamine phosphate solution </strong><br>ALK-Abello, Inc.<br></p></div>
<h1>Histamine Phosphate</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Directions for Use of</span></p>
<p><span class="Bold">Positive Skin Test Control </span><span class="Bold">- Histamine</span></p>
<p><span class="Bold">HISTATROL®</span></p>
<p>Histamine Base 1 mg/mL</p>
<p>(Histamine Phosphate 2.75 mg/mL)</p>
<p>in Glycerin 50% (v/v)</p>
<p><span class="Bold">For Percutaneous Testing</span></p>
<p>Histamine Base 0.1 mg/mL</p>
<p>(Histamine Phosphate 0.275 mg/mL)</p>
<p><span class="Bold">For Intracutaneous (Intradermal) Testing</span></p>
<p>Port Washington, New York 11050 </p>
<p>U.S. Government License No. 1256</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">The chemical formula for Histamine Phosphate is C<span class="Sub">5</span>H<span class="Sub">9</span><span class="Sub"> </span>N<span class="Sub">3</span> · 2H<span class="Sub">3</span> PO<span class="Sub">4</span>; its molecular weight is 307.14.  For prick, puncture or scratch testing, the product is a sterile solution that contains 1 mg/mL histamine base (2.75 mg/mL Histamine Phosphate) in Water for Injection; it also contains Glycerin 50% (v/v) as viscosity agent and Phenol 0.4% as preservative.  For intracutaneous (intradermal) skin testing, the product is a sterile solution that contains 0.1 mg/mL histamine base (0.275 mg/mL Histamine Phosphate) in Water for Injection and Phenol 0.4% as preservative. The product should be stored refrigerated and protected from light.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Histamine acts as a potent vasodilator when released from mast cells during an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.  It is largely responsible for the immediate skin test reaction of a sensitive patient when challenged with an offending allergen.</p>
<p>The effect of added Glycerin (50% v/v) to 1 mg/mL histamine base was studied by puncture testing using a bifurcated needle in twelve volunteer subjects.  The mean sum of cross-diameters of the <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span> was 13.25 mm (range 10-15 mm) for the non-glycerinated, and 12.54 mm (range 9-15 mm) for the glycerinated formulation.  Sum of cross-diameters of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> was 52.88 mm (range 23-92 mm) for the non-glycerinated, and 54.42 mm (range 19-87 mm) for the glycerinated formulation.  These differences are not statistically significant.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">For use as a positive control in evaluation of allergenic (<span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity</span> or "Type I") skin testing.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">Histamine should not be injected into individuals with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, severe cardiac, pulmonary, or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Not to be used for diagnosis of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> or to test the ability of the gastric mucosa to secrete hydrochloric acid.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">Care must be taken in intracutaneous testing to avoid injection into a venule or capillary.  Pull back gently on the syringe plunger and note if blood is drawn.  If blood is drawn, withdraw needle and inject into another skin site. </p>
<p>Small doses by any route of administration may precipitate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">bronchial hyperactivity</span>.  This product is not intended for inhalation, or subcutaneous injection. The utmost caution is advised in using histamine in such patients and in those with a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="_PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First">A separate sterile needle or other percutaneous testing device should be used for each individual patient to prevent transmission of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and other infectious agents from one person to another.</p>
<p>Epinephrine Injection (1:1,000) and injectable antihistamines should be available for immediate use in the event the patient exhibits a severe response.  A tourniquet can be applied above the test site to slow absorption if a severe response occurs.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First">Drugs can interfere with the performance of skin tests in general, and specifically with histamine<span class="Sup">1</span>.</p>
<p>Antihistamines: Response to histamine is suppressed by antihistamines.  The length of suppression varies, and is dependent on individual patient, type of antihistamine and length of time the patient has been on antihistamines.  The duration of this suppression may be as little as 24 hours (chlorpheniramine), and can be as long as 40 days (astemizole).</p>
<p>Tricyclic Antidepressants: These exert a potent and sustained decrease of skin reactivity to histamine, which may last for a few weeks.</p>
<p>Beta<span class="Sub">2</span> Agonists: Oral terbutaline and parenteral ephedrine, in general, have been shown to decrease allergen induced wheal. Theoretically, this may also reduce whealing capacity to histamine.</p>
<p>Dopamine: Intravenous infusion of dopamine has been shown to inhibit skin test responses to histamine.</p>
<p>Beta Blocking Agents: Propranolol can significantly increase skin test reactivity, including histamine.</p>
<p>Other Drugs: Short acting steroids, inhaled beta agonists, theophylline and cromolyn do not seem to affect skin test response.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility  </span></h2>
<p class="First">Animal studies have not been conducted with Histamine.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.4"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">It is not known if Histamine administered percutaneously or intracutaneously appears in human milk. Because many drugs are excreted in human milk, caution should be exercised when histamine is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2><span class="Bold">Pregnancy Category C</span></h2>
<p class="First">It is not known whether Histamine can cause fetal harm when administered during pregnancy or whether it can affect reproduction capacity.  Histamine should be given during pregnancy only if clearly needed.</p>
<p>There are no adequate and well-controlled studies during pregnancy.  However, based on histamine's known ability to contract uterine muscle, exposure or repeated doses should be avoided.</p>
<p>HISTATROL<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus or mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.6"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Histamine solutions for percutaneous testing have been given safely in infants and young children.<span class="Sup">2,3,4,5</span>  Neonates and infants have lower skin test reactivity to histamines as well as common allergens.<span class="Sup">3,4,5,6</span> About 20% of infants less than six months of age have been observed to have a negative reaction to histamine hydrochloride (1 mg/mL of salt).<span class="Sup">4</span>  Skin test reactivity gradually increases to age six and plateaus to age sixty.<span class="Sup">2,3</span>  Therefore, small skin test reactions should be anticipated in children under age six.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold">Local:</span></h2>
<p class="First">Reactions such as wheal, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and localized <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> are to be expected, but if very large (i.e. greater than 4+ as described dosage and administration) may be the first manifestation of a systemic reaction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold">Systemic:</span></h2>
<p class="First">Following the injection of large doses of histamine, systemic reactions may include <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, bronchial constriction, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, marked <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, metallic taste, and local or generalized allergic manifestations (see also <span class="Bold"><a href="#_OVERDOSAGE">OVERDOSAGE</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="_OVERDOSAGE"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">A large subcutaneous dose of Histamine Phosphate may cause severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">occipital headache</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal pain</span>, a rapid <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span>, and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> of the face.  Overdosage may cause severe symptoms including <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vasomotor collapse</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Epinephrine Injection 0.01 mg/kg to a maximum of 1.0 mg given subcutaneously or intramuscularly should be used in case of emergency due to severe reactions (see <a href="#_PRECAUTIONS">Precautions</a>).  An antihistamine preparation may be given intramuscularly to ameliorate systemic reaction to <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="Bold">For Prick, Puncture and Scratch Testing</span></h2>
<p class="First">Histamine base 1 mg/mL (Histamine Phosphate 2.75 mg/mL) should be used to give a reaction.  (Refer to Interpretation Section.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2><span class="Bold">Prick, Puncture or Scratch Test Techniques</span></h2>
<ol class="Arabic">
<li>The skin in the test area should be cleansed with alcohol and air dried.<br>
</li>
<li>The histamine control skin test solution should be placed at the same site with the other skin test antigens, either on the patient's back or on the volar surface of the forearm.  The patient should be placed in a comfortable position before the testing is begun.<br>
</li>
<li>For the prick test, a sharp needle is used to puncture the skin, but not to draw blood.  If the scratch test is used, carefully break or scratch the skin with a sterile scarifier. Do not draw blood.  Each scratch should be about 2 mm - 4 mm in length.<br>
</li>
<li>A small drop of the histamine base 1 mg/mL (Histamine Phosphate 2.75 mg/mL) is placed on the abraded skin site no closer than 4 or 5 cm from an adjacent test site.  Some physicians prefer to place the solution on the test area and then prick through the drop with a sharp needle.<br>
</li>
<li>Use a separate sterile scarifier or needle for each patient.<br>
</li>
<li>The test should be read at 15 minutes; if a large wheal reaction occurs before that time the test site should be wiped free of histamine.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2><span class="Bold">Interpretation</span></h2>
<p class="First">The patient's response is based on the size of: <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (degree of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>) and/or size of wheal (smooth, slightly elevated area) which appear after 10 minutes.</p>
<p>For percutaneous testing, different devices and/or techniques influence the size of the reaction.  Therefore, it is important to refer to the device manufacturer's or distributor's instructions when grading reactions.</p>
<p>For prick, puncture and scratch testing, histamine base 1 mg/mL (Histamine Phosphate 2.75 mg/mL) should be used to give a positive reaction.  In a large population, the NHANES II survey reports a mean diameter (average of length and width) wheal of 4.4 mm ± 1.65 mm (± standard deviation) and a mean <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of 18.4 mm ± 8.55 mm (± standard deviation) when using 25 gauge B-D needle by prick puncture (Pepys) technique.<span class="Sup">7</span>  All positive reactions should be interpreted against an appropriate negative control.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2><span class="Bold">For Intradermal Skin Testing</span></h2>
<p class="First">Histamine base 0.1 mg/mL (Histamine Phosphate 0.275 mg/mL) or 0.01 mg/mL should be used to give a reaction.  (Refer to Interpretation Section.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5"></a><p></p>
<h2><span class="Bold">Intracutaneously (Intradermal) Test Techniques</span></h2>
<ol class="Arabic">
<li>The skin should be cleansed with alcohol and air dried.<br>
</li>
<li>A sterile one milliliter tuberculin syringe with 26 or 27 gauge needle should be used.  A single sterile syringe should be used for each solution to assure <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span>.  Only the histamine base 0.1 mg/mL (Histamine Phosphate, 0.275 mg/mL) or greater dilution solution should be used.<br>
</li>
<li>The histamine base skin test solution should be injected at the same site with the other skin test allergens, either on the patient's back or on the arm.  The patient should be placed in a comfortable position before the testing is begun.<br>
</li>
<li>The skin is held <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tense</span> and the needle is inserted almost parallel to the skin, bevel side up, far enough to cover the beveled portion.  Slowly inject 0.01 mL or 0.02 mL, making a small bleb approximately 3 mm - 5 mm in diameter.<br>
</li>
<li>The test should be read in 15 minutes.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.6"></a><p></p>
<h2><span class="Bold">Interpretation</span></h2>
<p class="First">The patient's response is based on the size of: <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (degree of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>) and/or size of wheal (smooth, slightly elevated area) which appear after 10 minutes.</p>
<p>For intradermal skin testing, histamine base 0.1 mg/mL (Histamine Phosphate 0.275 mg/mL) or 0.01 mg/mL should be used to give a positive reaction.  The available 0.1 mg/mL concentration must be diluted ten-fold to achieve this dose.  All positive reactions should be interpreted against an appropriate negative control.  In two successive years of testing, the Committee on Standardization of the American College of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> reported positive reactions at histamine base doses of 0.01 mg/mL and higher.  Mean sum of wheal diameters was approximately 14 mm ± 4.8 mm and sum of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> diameter was approximately 52 mm ± 21.6 mm following 0.01 mL intradermal doses of 0.01 mg/mL histamine base.  When 0.01 mL of 0.1 mg/mL histamine base was injected, the sum of cross-diameters of wheal ranged from 15-20 mm and the sum of cross-diameters of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> ranged from 60-80 mm.<span class="Sup">8</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1><span class="Bold"><br>HOW SUPPLIED</span></h1>
<p class="First">Multidose vials containing 5 mL histamine base, 1 mg/mL (Histamine Phosphate 2.75 mg/mL) in Glycerin 50% (v/v) for prick, puncture, or scratch testing.  Multidose vials containing 5 mL histamine base, 0.1 mg/mL (Histamine Phosphate 0.275 mg/mL) in aqueous solution for intradermal testing.  Store at 2° - 8°C.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1><span class="Bold">REFERENCES</span></h1>
<ol class="Arabic">
<li>Bousquet, J.: In vivo methods for the study of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>: skin test, techniques, and interpretation.  In <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Principles and Practice, 3rd Edition, Middleton, et al eds., C.V. Mosby, St. Louis, MO, 1988.<br>
</li>
<li>Skassa-Brociek, W., et al: Skin test reactivity to histamine from infancy to old age. <span class="Italics"> J.</span> <span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Clin. Immunol</span>. <span class="Underline">80</span>:711, 1987.<br>
</li>
<li>Menardo, J.L., et al: Skin test reactivity in infancy.  <span class="Italics">J. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Clin. Immunol</span>.<span class="Underline"> 75</span>:646, 1985.<br>
</li>
<li>Van Asperen, P.P., et al: Skin test reactivity and clinical allergen sensitivity in infancy. <span class="Italics">J</span>. <span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Clin. Immunol</span>. <span class="Underline">73</span>:381, 1984.<br>
</li>
<li>Matheson, A., et al: Reactivity of the skin of the newborn infant. Pediatrics <span class="Underline">10</span>:181, 1952.<br>
</li>
<li>Stevenson, D.D., et al: Development of IgE in newborn human infants. <span class="Italics">J. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></span> <span class="Underline">48</span>:61, 1971.<br>
</li>
<li>National Center for Health Statistics, P.J. Gergen and P.C. Turkeltaub: Percutaneous <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity</span> to eight allergens, United States, 1976-80. Vital and Health Statistics.  Series 11, No. 235. DHHS Pub. No. (PHS) 86-1685. Public Health Service.  Washington. U.S. Government Printing Office, July 1986.<br>
</li>
<li>Committee on Standardization.  Report of the Committee on Standardization: 1.  A method of evaluating skin test response. <span class="Italics">Ann. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></span> <span class="Underline">29</span>:30-34, 1971.</li>
</ol>
<p class="First">Revision: June 2002</p>
<p>© Alk-Abello, Inc. 2002
		     
	
		     
	
		     
	
		     
	
		     
	
		     
	
		     
	
		     
	107J</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HISTAMINE POSITIVE 		
					SKIN TEST CONTROL</strong><br><span class="contentTableReg">histamine phosphate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0268-0248</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HISTAMINE PHOSPHATE</strong> (HISTAMINE) </td>
<td class="formItem">HISTAMINE PHOSPHATE</td>
<td class="formItem">0.275 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">0.004 mL  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0268-0248-05</td>
<td class="formItem">5 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103754</td>
<td class="formItem">10/23/1989</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HISTAMINE POSITIVE 		
					SKIN TEST CONTROL</strong><br><span class="contentTableReg">histamine phosphate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0268-0247</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">PERCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HISTAMINE PHOSPHATE</strong> (HISTAMINE) </td>
<td class="formItem">HISTAMINE PHOSPHATE</td>
<td class="formItem">2.75 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">0.004 mL  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">0.5 mL  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0268-0247-05</td>
<td class="formItem">5 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103754</td>
<td class="formItem">10/23/1989</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>ALK-Abello, Inc.
							(809998847)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>28517fe7-35ea-4ed9-af4c-2800c890460e</div>
<div>Set id: 1159c24c-d9ce-49a2-b0bd-dc27c710f146</div>
<div>Version: 1</div>
<div>Effective Time: 20090516</div>
</div>
</div> <div class="DistributorName">ALK-Abello, Inc.</div></p>
</body></html>
